<code id='6D094CEE31'></code><style id='6D094CEE31'></style>
    • <acronym id='6D094CEE31'></acronym>
      <center id='6D094CEE31'><center id='6D094CEE31'><tfoot id='6D094CEE31'></tfoot></center><abbr id='6D094CEE31'><dir id='6D094CEE31'><tfoot id='6D094CEE31'></tfoot><noframes id='6D094CEE31'>

    • <optgroup id='6D094CEE31'><strike id='6D094CEE31'><sup id='6D094CEE31'></sup></strike><code id='6D094CEE31'></code></optgroup>
        1. <b id='6D094CEE31'><label id='6D094CEE31'><select id='6D094CEE31'><dt id='6D094CEE31'><span id='6D094CEE31'></span></dt></select></label></b><u id='6D094CEE31'></u>
          <i id='6D094CEE31'><strike id='6D094CEE31'><tt id='6D094CEE31'><pre id='6D094CEE31'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:focus    Page View:869
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In